Evidence map›Paper›PMID 37139407›Full record

ArticleActa pharmaceutica Sinica. B2023

Yan Shi, Candy Lee, Peng Sang, Zaid Amso, David Huang, Weixia Zhong, Meng Gu, Lulu Wei, Vân T B Nguyen-Tran, Jingyao Zhang and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yan ShiDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Candy LeeCalibr at Scripps Research, La Jolla, CA 92037, USA.
Peng SangDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Zaid AmsoCalibr at Scripps Research, La Jolla, CA 92037, USA.
David HuangCalibr at Scripps Research, La Jolla, CA 92037, USA.
Weixia ZhongCalibr at Scripps Research, La Jolla, CA 92037, USA.
Meng GuDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Lulu WeiDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Vân T B Nguyen-TranCalibr at Scripps Research, La Jolla, CA 92037, USA.
Jingyao ZhangDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Weijun ShenCalibr at Scripps Research, La Jolla, CA 92037, USA.
Jianfeng CaiDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Scripps Institution of Oceanography · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptides are increasingly important resources for biological and therapeutic development, however, their intrinsic susceptibility to proteolytic degradation represents a big hurdle. As a natural agonist for GLP-1R, glucagon-like peptide 1 (GLP-1) is of significant clinical interest for the treatment of type-2 diabetes mellitus, but its

Indexed as

GLP-1GLP-1R agonistsHelical structuresPeptidomimeticsPharmacological activityRational designStabilityType-2 diabetes treatments

Identifiers

PMID37139407
PMCPMC10149899
OpenAlexW4307002300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.